11C-Erlotinib Outcome Parameters for Baseline Scan and Scan after Oral Dosing of Erlotinib
| Group | AUCbrain (SUV × min) | VT,Logan | VT,2T4K | K1 (mL/(g × min)) | k2 (1/min) | k3 (1/min) | k4 (1/min) |
| Baseline (n = 17) | 9.9 ± 2.2 | 0.17 ± 0.03 (1) | 0.14 ± 0.04 (6) | 0.022 ± 0.006 (10) | 0.232 ± 0.047 (15) | 0.029 ± 0.070 (50) | 0.080 ± 0.190 (40) |
| 300 mg (n = 7) | 14.3 ± 2.8* | 0.18 ± 0.03 (1) | 0.15 ± 0.03 (3) | 0.030 ± 0.010 (8) | 0.269 ± 0.061 (9) | 0.017 ± 0.006 (29) | 0.055 ± 0.018 (20) |
| 650 mg (n = 8) | 18.6 ± 2.7* | 0.19 ± 0.04 (1)* | 0.16 ± 0.04 (1)* | 0.032 ± 0.006 (6)* | 0.273 ± 0.028 (8)* | 0.022 ± 0.013 (21) | 0.059 ± 0.030 (13) |
| 1,000 mg (n = 2) | 20.1 ± 3.8 | 0.26 ± 0.00 (1) | 0.23 ± 0.01 (1) | 0.043 ± 0.01 (5) | 0.251 ± 0.022 (7) | 0.020 ± 0.016 (21) | 0.055 ± 0.016 (14) |
↵* P < 0.05 for comparison with individual baseline scan using Wilcoxon matched-pairs signed-rank test.
AUCbrain = area under brain time–activity curve; K1, k2, k3, k4 = rate constants for transfer of radioactivity between plasma, first, and second brain tissue compartments calculated with 2-tissue–4-rate-constant (2T4K) compartment model; VT,2T4K = total VT calculated with 2T4K model.
Outcome parameters are given as mean ± SD averaged over all subjects per group. Value in parentheses represents precision of parameter estimates (expressed as their coefficient of variation in percentage).